Browse the evidence

Adaptive thermogenesis is associated with significant hormonal changes, specifically decreased leptin and T3, and reduced resting heart rate.

Low leptin and T3 levels are expected during a cut and contribute to metabolic slowdown. This is a normal hormonal response to energy deficit.

Increasing urinary sodium excretion by 1 gram per day is associated with a significant increase in systolic blood pressure (approx. 1.7 mmHg) and diastolic blood pressure (approx. 0.5 mmHg).

For every additional gram of sodium you consume (roughly 1/3 of a teaspoon of table salt), your systolic blood pressure may rise by about 1.7 mmHg. To mitigate this, ensure your potassium intake is adequate, as the study shows potassium helps lower blood pressure.

Increasing urinary potassium excretion by 1 gram per day is associated with a significant decrease in systolic blood pressure (approx. 1.1 mmHg) and diastolic blood pressure (approx. 0.9 mmHg).

Increasing your potassium intake by 1 gram per day can lower your systolic blood pressure by about 1.1 mmHg. Focus on potassium-rich foods like fruits and vegetables to help counteract the effects of sodium.

A higher sodium-to-potassium ratio (gram-to-gram) is significantly associated with increased systolic and diastolic blood pressure, with the effect being most pronounced in low-salt regions.

Your sodium-to-potassium ratio is a critical determinant of blood pressure. A higher ratio (more sodium relative to potassium) significantly raises blood pressure. To lower your ratio, reduce sodium intake and increase potassium-rich foods, especially if you live in a region with lower salt intake.

GLP-1RAs reduce food intake and body weight by activating POMC neurons and inhibiting NPY/AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus.

GLP-1 medications also work in the brain's 'hunger center' (arcuate nucleus) by boosting 'stop eating' signals (POMC) and reducing 'start eating' signals (NPY/AgRP). This dual action helps reduce overall food intake and body weight.

Discontinuation of anti-obesity medications (AOMs) leads to significant weight regain starting at 8 weeks post-treatment, with the trajectory stabilizing by 26 weeks.

If you stop taking anti-obesity medication, expect to regain weight starting around 2 months later. This is a biological response to the loss of the drug's appetite-suppressing effects, not a lack of willpower. Long-term management likely requires ongoing treatment or intensive lifestyle support to counteract this regain.

Adherence to the Mediterranean diet (MeDi) is associated with improved cognitive performance and a delay in cognitive decline in elderly populations, particularly when enriched with extra virgin olive oil or nuts.

Adopt a Mediterranean-style eating pattern focusing on extra virgin olive oil, vegetables, fruits, whole grains, and nuts. This approach is more effective for cognitive health than taking single supplements. Prioritize high-polyphenol olive oil and moderate wine intake if appropriate for your health profile.

Plant-based diets, particularly those emphasizing nutritious plant foods, are associated with a reduced risk of cognitive impairment and dementia compared to non-vegetarian diets.

Shift your diet to center around plants: vegetables, fruits, whole grains, legumes, nuts, and seeds. This pattern is linked to a significantly lower risk of dementia. Ensure you are eating 'nutritious' plant foods, as less healthy plant-based patterns may not offer the same benefits.

In well-trained males, the time course of recovery (muscle damage and performance fatigue) following volume-type resistance training (4 sets to failure at 80% 1RM) is similar for the back squat, bench press, and deadlift, refuting the belief that the deadlift requires significantly longer recovery.

If you are a well-trained male, you do not need to schedule significantly more rest days between deadlift sessions compared to squat or bench press sessions, provided you are doing similar volume (e.g., 4 sets to failure at 80% 1RM). You can likely train these movements with similar frequency (e.g., 2-3 times per week) without one causing disproportionately longer fatigue than the others.

GLP-1 analogs and SGLT-2 inhibitors are promising therapeutic modalities for the obese-diabetic phenotype of HFpEF, with GLP-1 analogs showing significant reduction in epicardial adipose tissue (EAT) and body weight.

Newer diabetes drugs (GLP-1s and SGLT-2 inhibitors) are highly effective for obese HFpEF patients. They help lose weight, reduce heart fat (EAT), and improve heart function. GLP-1s like semaglutide can lead to substantial weight loss (up to 10% or more).

Triple agonists (GLP-1/GIP/Glucagon) like retatrutide achieve even greater weight loss (>24%) than dual agonists, likely due to the addition of glucagon receptor agonism which increases energy expenditure.

Triple-agonist injections like retatrutide (12 mg/week) are showing even higher weight loss rates (~24%) than current dual agonists in early trials. This is due to the addition of glucagon stimulation, which boosts energy expenditure. These are still in development and not yet widely approved for obesity.

Metformin is the preferred initial oral hypoglycemic agent for Type 2 Diabetes Mellitus due to its excellent blood glucose-lowering effect, relatively low side effects, long-term safety, low risk of hypoglycemia, and low weight gain.

Start metformin at a low dose and increase it slowly to minimize stomach upset. It is the standard first-line treatment because it lowers blood sugar effectively without causing significant weight gain or hypoglycemia.

DPP4 inhibitors are effective substitutes for metformin with low hypoglycemia risk, but their cardiovascular effects are neutral and they may slightly increase heart failure risk.

DPP4 inhibitors are a good option if metformin is not tolerated, offering low hypoglycemia risk. However, they do not provide cardiovascular benefits and may have a slight risk of heart failure.

Low intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) significantly amplifies the cardiovascular disease (CVD) risk associated with having a family history of CVD, whereas low intake of other polyunsaturated fatty acids (linoleic acid and alpha-linolenic acid) does not show this interaction.

If you have a family history of heart disease, your risk is significantly higher if your levels of EPA and DHA (found in oily fish) are low. While general healthy fats are good, ensuring adequate intake of EPA/DHA is specifically critical for you to mitigate this genetic risk. Aim to consume oily fish regularly to raise these biomarkers.

Physical activity alone is an effective strategy for reducing obesity and related comorbidities, particularly abdominal fat, even without dietary energy restriction.

To lose fat, you do not necessarily need to diet. Engaging in 45-60 minutes of moderate exercise daily is sufficient to reduce body mass and abdominal fat. Focus on consistency rather than extreme intensity if you are not restricting calories.

Exercise interventions typically result in less weight loss than predicted by simple energy balance models due to metabolic and behavioral compensation.

Do not be discouraged if you do not lose weight as fast as you calculate. Your body will try to compensate by making you hungrier or moving less. Focus on the health benefits and consistency rather than just the scale.

Bariatric surgery significantly reduces the incidence of new-onset type 2 diabetes, hypertension, and dyslipidemia in severely obese individuals compared to no intervention.

For severely obese individuals, bariatric surgery is a highly effective preventive measure against developing type 2 diabetes, high blood pressure, and high cholesterol. The study shows that surgery reduces the risk of developing these conditions by 55-94% compared to no treatment. This should be a key factor in treatment decisions for severe obesity, especially in regions with high metabolic disease rates.

Intensive lifestyle interventions (caloric restriction and physical activity) can induce significant weight loss (5-10%) and improve glycemic control in type 2 diabetes, but long-term maintenance is difficult due to physiological counter-regulation (increased appetite/hormonal resistance).

Start with lifestyle changes (diet and exercise) as they are the foundation of treatment. Aim for 5-10% weight loss to improve health. Be aware that your body will fight back with increased hunger after you lose weight. If you struggle to maintain weight loss long-term, consider adding medications that help counteract this hunger.

Insulin and Sulfonylureas cause weight gain in T2D patients, which exacerbates insulin resistance and creates a cycle requiring further treatment intensification.

Be aware that insulin and sulfonylureas can cause weight gain. If you are gaining weight on these medications, discuss alternatives with your doctor that do not cause weight gain.

Initiating combination therapy at the time of diagnosis for Type 2 Diabetes is scientifically supported to improve durability of glycaemic control and reduce complications, yet is underutilized due to 'clinical inertia'.

If your blood sugar is high at diagnosis, do not accept being put on just one medication if your doctor suggests it might not be enough. The paper argues that starting with a combination of drugs early on is scientifically better for long-term control and prevents complications. Ask your doctor why combination therapy isn't being used if your levels are high. Do not let 'clinical inertia' (delaying treatment) prevent you from getting the best possible control from the start.

A high carbohydrate-to-fat intake ratio (specifically high carbohydrate and low fat intake) is associated with lower long-term HDL-cholesterol levels and a significantly increased risk of incident hypo-HDL-cholesterolemia.

If you eat a diet very high in carbohydrates and very low in fat (like a traditional Korean diet heavy in white rice), your HDL 'good' cholesterol levels tend to be lower over time, and your risk of developing low HDL increases. To support healthy HDL levels, ensure your carbohydrate intake is balanced with adequate fat intake, rather than maximizing carbs while minimizing fat.

Bariatric surgery yields significantly higher rates of complete and prolonged diabetes remission compared to usual care (lifestyle and medication management).

For patients with Type 2 Diabetes, bariatric surgery is a more effective intervention for achieving remission than lifestyle changes and medications alone. While surgery carries risks and potential for relapse, the data shows it significantly outperforms standard care in both complete and prolonged remission rates. Patients should discuss their eligibility and specific surgical options (like RYGB or Sleeve Gastrectomy) with their healthcare provider, weighing the higher remission probability against surgical risks.

Bariatric surgery patients often have higher baseline HbA1c and require more insulin, yet still achieve higher remission rates than usual care patients.

Even if your diabetes is severe (high HbA1c) or you require insulin, bariatric surgery may still offer a chance for remission, potentially more so than lifestyle changes alone. Do not rule out surgery solely based on the severity of your diabetes or current medication use.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and slow chronic kidney disease progression in Type 2 Diabetes, but evidence for improving heart failure outcomes is mixed or insufficient.

If you have Type 2 Diabetes and high heart risk or kidney issues, GLP-1 agonists (like Ozempic, Trulicity, or Victoza) are highly recommended to prevent heart attacks and protect kidneys. However, they are not currently proven to treat existing heart failure. If you struggle with injections, ask about oral semaglutide.